medigraphic.com
ISSN 1527-3172 (Electronic)

2016, Number 1-2

<< Back Next >>

MEDICC Review 2016; 18 (1-2)

Blood-based biomarkers could help identify subclinical brain damage caused by arterial hypertension

González-Quevedo A, González-García S, Peña-Sánchez M, Menéndez-Saínz C, Fernández-Carriera R, Cordero-Einz A

Language: English
References: 74
Page: 46-53
PDF size: 181.72 Kb.


ABSTRACT

Arterial hypertension is the most prevalent non-communicable disease worldwide, and has long been recognized as a major risk factor for cardiovascular and cerebrovascular diseases. High blood pressure has deleterious consequences on the main target organs (heart, kidney, brain), and several studies have shown that brain damage is more frequent than heart and kidney involvement. Silent lesions can subsequently lead to cognitive decline, dementia or stroke.
Nevertheless, screening for subclinical brain deterioration is rarely performed because it requires imaging techniques whose scarcity and high cost rule out routine use by primary care physicians. The challenge is thus early detection of asymptomatic brain lesions with cost-effective techniques to test thousands of patients in the community. In this review we present an update on the status of biomarkers explored as alternatives for early detection of brain damage in arterial hypertension, potentially useful to identify patients needing referrals for brain MRI: ambulatory blood pressure monitoring, quantitative retinal microvascular assessment, quantitative electroencephalography, carotid ultrasonography, neurocognitive studies and blood-based biomarkers. We place special emphasis on blood-based biomarkers, for which our group reported the first preliminary evidence of an association between serum neuron-specific enolase and severity of white matter lesions in patients with essential hypertension. This review consequently explores the potential for blood-based biomarkers to provide a faster, cheaper and more accessible early-detection solution, particularly beneficial in resource-limited settings such as Cuba’s.


REFERENCES

  1. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial HT: the task force for the management of arterial HT of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281–357.

  2. Maillard P, Seshadri S, Beiser A, Himali J, Au R, Fletcher E, et al. Effects of systolic blood pressure on white-matter integrity in young adults in the Framingham Heart Study: a cross-sectional study. Lancet Neurol. 2012 Dec;11(12):1039–47.

  3. Huang Y, Cai X, Li Y, Su L, Mai W, Wang S, et al. Prehypertension and the risk of stroke: a metaanalysis. Neurology. 2014 Apr 1;82(13):1153–61.

  4. Rossignol P, Hosseini K, Tropeano AI, Faya R, Tsatsaris A, Guillemin F, et al. Target organ damage assessment in French hypertensive patients without established cardiovascular or renal disease: results of the PREVENT-A study. J Hypertens. 2013 Jan;31(1):177–85.

  5. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfi eld MJ, et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009 Nov;27(11):2121–58.

  6. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 2007 Jul;6(7):611–9.

  7. Henskens LH, van Oostenbrugge RJ, Kroon AA, Hofman PA, Lodder J, de Leeuw PW. Detection of silent cerebrovascular disease refi nes risk stratifi cation of hypertensive patients. J Hypertens. 2009 Apr;27(4):846–53.

  8. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010 Jul;9(7):689–701.

  9. Scuteri A, Nilsson PM, Tzourio C, Redon J, Laurent S. Microvascular brain damage with aging and hypertension: pathophysiological consideration and clinical implications. J Hypertens. 2011 Aug;29(8):1469–77.

  10. Bernick C, Kuller L, Dulberg C, Longstreth WT Jr, Manolio T, Beauchamp N, et al. Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology. 2001 Oct 9;57(7):1222–9.

  11. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke. 2003 May;34(5):1126–9.

  12. Longstreth WT, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, et al. Clinical correlates of white matter fi ndings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke. 1996 Aug;27(8):1274–82.

  13. Sierra C. Essential hypertension, cerebral white matter pathology and ischemic stroke. Curr Med Chem. 2014;21(19):2156–64.

  14. Liao D, Cooper L, Cai J, Toole JF, Bryan NR, Hutchinson RG, et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Stroke. 1996 Dec;27(12):2262–70.

  15. Longstreth WT Jr, Bernick C, Manolio TA, Bryan N, Jungreis CA, Price TR. Lacunar infarcts defi ned by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol. 1998 Sep;55(9):1217–25.

  16. van Boxtel M, Henskens LH, Kroon AA, Hofman PA, Gronenschild EH, Jolles J, et al. Ambulatory blood pressure, asymptomatic cerebrovascular damage and cognitive function in essential hypertension. J Hum Hypertens. 2006 Jan;20(1):5–13.

  17. Hernández-González G, Bringas-Vega ML, Galán-García L, Bosch-Bayard J, LorenzoCeballo Y, Melie García L, et al. Multimodal quantitative neuroimaging databases and methods: the Cuban Brain Mapping Project. Clin EEG Neurosci. 2011 Jul;42(3):149–59.

  18. González-Quevedo A, García SG, Concepción OF, Freixas RS, Quevedo Sotolongo LQ, Mené- ndez MC, et al. Increased serum S-100B and neuron specifi c enolase–potential markers of early nervous system involvement in essential hypertension. Clin Biochem. 2011 Feb;44(2–3):154–9.

  19. González-García S, Hernández-Díaz Z, Quevedo-Sotolongo L, Peña-Sánchez M, PinoPeña Y, Fernández-Carriera R, et al. Resistive cerebral blood fl ow as a potential marker of subclinical brain damage in essential hypertension. World J Cardiovasc Dis. 2014;4(4):169–78.

  20. Van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke. 2008 Oct;39(10):2712–9.

  21. Gottesman RF, Coresh J, Catellier DJ, Sharrett AR, Rose KM, Coker LH, et al. Blood pressure and white-matter disease progression in a biethnic cohort: Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2010 Jan;41(1):3–8.

  22. Sierra C. Associations between ambulatory blood pressure parameters and cerebral white matter lesions. Int J Hypertens. 2011;2011:478710. DOI: 10.4061/2011/478710.

  23. De Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, Jolles J, et al. Cerebral WML and cognitive function: the Rotterdam Scan Study. Ann Neurol. 2000;47:145–51.

  24. Prabhakaran S, Wright CB, Yoshita M, Delapaz R, Brown T, DeCarli C, et al. Prevalence and determinants of subclinical brain infarction: the Northern Manhattan Study. Neurology. 2008 Feb 5;70(6):425–30.

  25. Wright CB, Festa JR, Paik MC, Schmiedigen A, Brown TR, Yoshita M, et al. White matter hyperintensities and subclinical infarction: associations with psychomotor speed and cognitive fl exibility. Stroke. 2008 Mar;39(3):800–5.

  26. Delgado P, Riba-Llena I, Tovar JL, Jarca CI, Mundet X, López-Rueda A, et al. Prevalence and associated factors of silent brain infarcts in a Mediterranean cohort of hypertensives. Hypertension. 2014 Sep;64(3):658–63.

  27. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated defi nition of stroke for the 21st century: a statement for health care professionals from the American Heart Association/American Stroke Association. Stroke. 2013 Jul;44(7):2064–89.

  28. Kitagawa K. Cerebral blood fl ow measurement by PET in hypertensive subjects as a marker of cognitive decline. J Alzheimers Dis. 2010;20(3):855–9.

  29. Dijkhuizen RM. Advances in MRI-based detection of cerebrovascular changes after experimental traumatic brain injury. Transl Stroke Res. 2011 Dec;2(4):524–32.

  30. Cheung CY, Tay WT, Mitchell P, Wang JJ, Hsu W, Lee ML, et al. Quantitative and qualitative retinal microvascular characteristics and blood pressure. J Hypertens. 2011 Jul;29(7):1380–91.

  31. Grassi G, Schmieder RE. The renaissance of the retinal microvascular network assessment in hypertension: new challenges. J Hypertens. 2011 Jul;29(7):1289–91.

  32. De Quesada-Martínez M, Blanco-García M, Díaz-Quesada L. Alteraciones funcionales cerebrales tempranas en pacientes con hipertensión arterial no complicada. Rev Neurol. 2005 Feb 16–28;40(4):199–209. Spanish.

  33. Goldstein B, Bartzokis G, Guthrie D, Shapiro D. Ambulatory blood pressure and the brain: a 5-year follow-up. Neurology. 2005 Jun 14;64(11):1846–52.

  34. Avet J, Pichot V, Barthélémy JC, Laurent B, Garcin A, Roche F, et al. Leukoaraiosis and ambulatory blood pressure load in a healthy elderly cohort study: the PROOF study. Int J Cardiol. 2014 Mar 1;172(1):59–63.

  35. Scheie HG. Evaluation of ophthalmoscopic changes of hypertension and arteriolar sclerosis. AMA Arch Ophthalmol. 1953 Feb;49(2):117–38.

  36. Wong TY, Klein R, Sharrett AR, Couper DJ, Klein BE, Liao DP, et al. Cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA. 2002 Jul;288(1):67–74.

  37. De Quesada Martínez ME, Reyes Moreno M. Localización de la actividad paroxística en pacientes con hipertensión arterial con el uso de la tomografía electromagnética de baja resolución (LORETA). Vitae Acad Bioméd Digital [Internet]. 2010 [cited 2015 Apr 17];44. Available from: http://dialnet.unirioja.es/servlet/articulo?co digo=3749913. Spanish.

  38. Brown Martínez M, Valdés-González Y, GonzálezOrtiz E, Hernández-González G, Valdés Sosa P, Galán García L, et al. [Use of electroencephalography to identify asymptomatic cerebrovascular lesions among hypertensives]. Rev Cub Investig Bioméd. 2014;33:231–40. Spanish.

  39. Kearney-Schwartz A, Rossignol P, Bracard S, Felblinger J, Fay R, Boivin JM, et al. Vascular structure and function is correlated to cognitive perfor mance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. Stroke. 2009 Apr;40(4):1229–36.

  40. Heliopoulos I, Artemis D, Vadikolias K, Tripsianis G, Piperidou C, Tsivgoulis G. Association of ultrasonographic parameters with subclinical white-matter hyperintensities in hypertensive patients. Cardiovasc Psychiatry Neurol. 2012; 2012:616572. DOI: 10.1155/2012/616572.

  41. Scuteri A. Brain injury as end-organ damage in hypertension. Lancet Neurol. 2012 Dec;11(12):1015–7.

  42. Gąsecki D, Kwarciany M, Nyka W, Narkiewicz K. Hypertension, brain damage and cognitive decline. Curr Hypertens Rep. 2013 Dec;15(6):547–58.

  43. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010 Jan 9;375(9709):132–40.

  44. Jiménez MC, Rexrode KM, Glynn RJ, Ridker PM, Gaziano JM, Sesso HD. Association between high-sensitivity C-reactive protein and total stroke by hypertensive status among men. J Am Heart Assoc. 2015 Sep 21;4(9):e002073. DOI: 10.1161/JAHA.115.002073.

  45. Wright CB, Moon Y, Paik MC, Brown TR, Rabbani L, Yoshita M, et al. Infl ammatory biomarkers of vascular risk as correlates of leukoariosis. Stroke. 2009 Nov;40(11):3466–71.

  46. Satizabal CL, Zhu YC, Mazoyer B, Dufouil C, Tzourio C. Circulating IL-6 and CRP are associated with MRI fi ndings in the elderly: the 3C-Dijon Study. Neurology. 2012 Mar 6;78(10):720-7. DOI: 10.1212/WNL.0b013e318248e50f. Epub 2012 Feb 22.

  47. Mitaki S, Nagai A, Oguro H, Yamaguchi S. C-reactive protein levels are associated with cerebral small vessel-related lesions. Acta Neurol Scand. 2015 May 14. DOI: 10.1111/ ane.12440. [Epub ahead of print]

  48. Abe A, Nishiyama Y, Harada-Abe M, Okubo S, Ueda M, Mishina M, et al. Relative risk values of age, acrolein, IL-6 and CRP as markers of periventricular hyperintensities: a cross-sectional study. BMJ Open. 2014;4(8):e005598.

  49. Shoamanesh A, Preis SR, Beiser AS, Vasan RS, Benjamin EJ, Kase CS, et al. Infl ammatory biomarkers, cerebral microbleeds, and small vessel disease. Framingham Heart Study. Neurology. 2015 Feb 24;84(8):825–32.

  50. Kim CK, Lee SH, Kim BJ, Ryu WS, Choi SH, Oh BH, et al. Elevated leukocyte count in asymptomatic subjects is associated with a higher risk for cerebral white matter lesions. Clin Neurol Neurosurg. 2011 Apr;113(3):177–80.

  51. Hudson BI, Moon YP, Kalea AZ, Khatri M, Marquez C, Schmidt AM, et al. Association of serum soluble Receptor for Advanced Glycation Endproducts with subclinical cerebrovascular disease: The Northern Manhattan Study (NOMAS). Atherosclerosis. 2011 May;216(1):192–8.

  52. Dadu RT, Fornage M, Virani SS, Nambi V, Hoogeveen RC, Boerwinkle E, et al. Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study. Stroke. 2013 Jul;44(7):1803–8.

  53. Reinhard H, Garde E, Skimminge A, Åkeson P, Ramsøy TZ, Winther K, et al. Plasma NTproBNP and white matter hyperintensities in type 2 diabetic patients. Cardiovasc Diabetol. 2012 Oct 3;11:119. DOI: 10.1186/1475-2840-11-119.

  54. de Leeuw FE, de Kleine M, Frijns CJ, Fijnheer R, van Gijn J, Kappelle LJ. Endothelial cell activation is associated with cerebral white matter lesions in patients with cerebrovascular disease. Ann NY Acad Sci. 2002 Nov;977:306–14.

  55. Markus HS, Hunt B, Palmer K, Enzinger C, Schmidt H, Schmidt R. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke prevention study. Stroke. 2005 Jul;36(7):1410–4.

  56. Abraham HM, Wolfson L, Moscufo N, Guttmann CR, Kaplan RF, White WB. Cardiovascular risk factors and small vessel disease of the brain: Blood pressure, white matter lesions, and functional decline in older persons. J Cereb Blood Flow Metab. 2016;36(1):132–42.

  57. Cheng F, Yuan Q, Yang J, Wang W, Liu H. The prognostic value of serum neuron-specifi c enolase in traumatic brain injury: systematic review and meta-analysis. PLoS One. 2014 Sep 4;9(9):e106680. DOI:10.1371/journal.pone .0106680.

  58. Di Pietro V, Amorini AM, Lazzarino G, Yakoub KM, D’Urso S, Lazzarino G, et al. S100B and glial fi brillary acidic protein as indexes to monitor damage severity in an in vitro model of traumatic brain injury. Neurochem Res. 2015 May;40(5):991–9.

  59. Shinozaki K, Oda S, Sadahiro T, Nakamura M, Hirayama Y, Abe R, et al. S-100B and neuronspecifi c enolase as predictors of neurological outcome in patients after cardiac arrest and return of spontaneous circulation: a systematic review. Crit Care. 2009;13(4):R121.

  60. Pearlman DM, Brown JR, MacKenzie TA, Hernandez F Jr, Najjar S. Blood levels of S-100 calcium-binding protein B, high-sensitivity C-reactive protein, and interleukin-6 for changes in depressive symptom severity after coronary artery bypass grafting: prospective cohort nested within a randomized, controlled trial. PLoS One. 2014 Oct 20;9(10):e111110. DOI:10.1371/journal.pone .0111110

  61. Strathmann FG, Schulte S, Goerl K, Petron DJ. Blood-based biomarkers for traumatic brain injury: evaluation of research approaches, available methods and potential utility from the clinician and clinical laboratory perspectives. Clin Biochem. 2014 Jul;47(10–11):876–88.

  62. Gazzolo D, Li Volti G, Gavilanes AW, Scapagnini G. Biomarkers of brain function and injury: biological and clinical signifi cance. Biomed Res Int [Internet]. 2015 [cited 2015 Apr 17];2015:389023. Available from: http://dx.doi .org/10.1155/2015/389023

  63. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and benefi cial. Mol Med. 2002 Aug;8(8):495–505.

  64. Dalmau J. Name a brain protein, and an autoantibody shall be found! Neurol Neuroimmunol Neuroinfl am. 2015 Oct 8;2(5):e159. DOI: 10.1212/ NXI.0000000000000159.

  65. Zerche M, Weissenborn K, Ott C, Dere E, Asif AR, Worthmann H, et al. Preexisting serum autoantibodies against the NMDAR subunit NR1 modulate evolution of lesion size in acute ischemic stroke. Stroke. 2015 May;46(5):1180–6.

  66. Dambinova SA, Kounteev GA, Skoromets AA. Multiple panel of biomarkers for TIA/stroke evaluation. Stroke. 2002 May;33(5):1180–1.

  67. Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003 Oct;49(10):1752–62.

  68. Weissman JD, Khunteev GA, Heath R, Dambinova SA. NR2 antibodies: risk assessment of transient ischemic attack (TIA)/stroke in patients with history of isolated and multiple cerebrovascular events. J Neurol Sci. 2011 Jan 15;300 (1–2):97–102.

  69. Gruden MA, Elistratova EI, Kudrina MV, Karlina VP, Deryabina IB, Semenova IM, et al. Content of S100b protein, HLDF24 peptide and autoantibodies to these factors as potential biomarkers for arterial hypertension in blood serum of healthy people. Bull Exp Biol Med. 2014 Feb;156(4):426–9.

  70. Schmidt AP, Tort AB, Amaral OB, Schmidt AP, Walz R, Vettorazzi-Stuckzynski J, et al. Serum S100B in pregnancy-related hypertensive disorders: a case–control study. Clin Chem. 2004 Feb;50(2):435–8.

  71. Al-Rawi NH, Atiyah KM. Salivary neuron specifi c enolase: an indicator for neuronal damage in patients with ischemic stroke and stroke-prone patients. Clin Chem Lab Med. 2009;47(12):1519–24.

  72. González-Quevedo A, González-García S, Hernández-Díaz Z, Fernández-Concepción O, Quevedo-Sotolongo L, Peña-Sánchez M, et al. Serum neuron specifi c enolase could predict subclinical brain damage and the subsequent occurrence of brain related vascular events during follow up in essential hypertension. J Neurol Sci. 2016;363:158–163.

  73. Bonet Gorbea M, Varona Pérez P. III Encuesta Nacional de factores de riesgo y actividades preventivas de enfermedades no transmisibles. Cuba 2010–2011 [Internet]. Havana: Editorial Ciencias Médicas; 2015 [cited 2015 Apr 13]. p. 140–65. Available from: http://www.bvs.sld.cu/ libros/encuesta_nacional_riesgo/hipertension .pdf. Spanish.

  74. Pérez Caballero MD, Dueñas Herrera A, Alfonzo Guerra JP, National Technical Committee for the Arterial Hypertension Program. Hipertensión arterial. Guía para la prevención, diagnóstico y tratamiento. Havana: Editorial Ciencias Médicas; 2008. Spanish.




2020     |     www.medigraphic.com